Safety and Compliance of Capecitabine and Temozolomide in Patients with Advanced Neuroendocrine Tumours

#1356

Introduction: Capecitabine-temozolomide (CAPTEM) is a treatment option in patients (pts) with neuroendocrine tumours. Although efficacy data has been reported, no detailed safety information exists.

Aim(s): The aim of this retrospective study was to examine safety and treatment compliance in CAPTEM-treated pts with diverse advanced NETs.

Materials and methods: Pts were treated with CAP 750mg/m2 BD (day1-14) and TEM 200mg/m2 OD (day10-14) orally in a 28 day cycle up to a maximum of 6 cycles. Alive pts completed retrospectively a treatment satisfaction survey.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Papaxoinis G

Authors: Papaxoinis G, McCallum L, Nasralla M, Hubner R, McNamara M,

Keywords: capecitabine, temozolomide, NET,